Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
4,5 Clinical outcomes Across phase II data for the once-daily, non-peptide GLP-1R agonist orforglipron in obese adults without diabetes, mean weight loss of 9.414.7% 6 was reported by week 36, depending on the dose, as compared to 2.3% with placebo
27-34 Of note, several trials in the PIONEER program used two estimands to further distinguish their analyses: 1) a treatment-policy estimand, which used data collected at the end of the study period (e.g., week 26 or 52) in the analysis regardless of treatment discontinuation or use of rescue medication
M.Krogdahl
doi: 10.3390/molecules201219800 101
US$ 29.60
US$ 29.85
US$ 23.72
US$ 22.91
